These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28927712)

  • 1. Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry study.
    Nikanorova M; Brandt C; Auvin S; McMurray R
    Epilepsy Behav; 2017 Nov; 76():63-70. PubMed ID: 28927712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial.
    Ohtsuka Y; Yoshinaga H; Shirasaka Y; Takayama R; Takano H; Iyoda K
    Epilepsy Res; 2016 Mar; 121():1-7. PubMed ID: 26827266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan.
    Ohtsuka Y; Yoshinaga H; Shirasaka Y; Takayama R; Takano H; Iyoda K
    Epilepsy Res; 2014 Nov; 108(9):1627-36. PubMed ID: 25219353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with Lennox-Gastaut syndrome: Final results from randomized study 303.
    Arzimanoglou A; Ferreira J; Satlin A; Olhaye O; Kumar D; Dhadda S; Bibbiani F
    Eur J Paediatr Neurol; 2019 Jan; 23(1):126-135. PubMed ID: 30309816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice.
    Striano P; McMurray R; Santamarina E; Falip M
    Epileptic Disord; 2018 Feb; 20(1):13-29. PubMed ID: 29313492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosing considerations for rufinamide in patients with Lennox-Gastaut syndrome: Phase III trial results and real-world clinical data.
    Kothare S; Kluger G; Sachdeo R; Williams B; Olhaye O; Perdomo C; Bibbiani F
    Seizure; 2017 Apr; 47():25-33. PubMed ID: 28284045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study.
    Arzimanoglou A; Ferreira JA; Satlin A; Mendes S; Williams B; Critchley D; Schuck E; Hussein Z; Kumar D; Dhadda S; Bibbiani F
    Eur J Paediatr Neurol; 2016 May; 20(3):393-402. PubMed ID: 26805435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rufinamide efficacy and safety in children aged 1-4 years with Lennox-Gastaut syndrome.
    Kim SH; Kang HC; Lee JS; Kim HD
    Brain Dev; 2018 Nov; 40(10):897-903. PubMed ID: 30166208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome.
    McCormack PL
    Pharmacoeconomics; 2012 Mar; 30(3):247-56. PubMed ID: 22332960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and tolerability of rufinamide in children and young adults with Lennox-Gastaut syndrome: a single center study in Korea.
    Lee EH; Yum MS; Ko TS
    Clin Neurol Neurosurg; 2013 Jul; 115(7):926-9. PubMed ID: 23083943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of rufinamide as adjunctive therapy in patients with Lennox Gastaut syndrome: A systematic review and Meta-analysis.
    Sharawat IK; Panda PK; Panda P; Dawman L
    Seizure; 2021 Oct; 91():296-307. PubMed ID: 34273668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome.
    Wisniewski CS
    Ann Pharmacother; 2010 Apr; 44(4):658-67. PubMed ID: 20233912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rufinamide in children and adults in routine clinical practice.
    Jaraba S; Santamarina E; Miró J; Toledo M; Molins A; Burcet J; Becerra JL; Raspall M; Pico G; Miravet E; Cano A; Fossas P; Fernández S; Falip M
    Acta Neurol Scand; 2017 Jan; 135(1):122-128. PubMed ID: 26923380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience.
    Kluger G; Kurlemann G; Haberlandt E; Ernst JP; Runge U; Schneider F; Makowski C; Boor R; Bast T
    Epilepsy Behav; 2009 Mar; 14(3):491-5. PubMed ID: 19162229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
    Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox-Gastaut Syndrome.
    Kessler SK; McCarthy A; Cnaan A; Dlugos DJ
    Epilepsy Res; 2015 May; 112():18-26. PubMed ID: 25847334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rufinamide from clinical trials to clinical practice in the United States and Europe.
    Resnick T; Arzimanoglou A; Brown LW; Flamini R; Kerr M; Kluger G; Kothare S; Philip S; Harrison M; Narurkar M
    Epileptic Disord; 2011 May; 13 Suppl 1():S27-43. PubMed ID: 21669560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive, adaptive, and behavioral effects of adjunctive rufinamide in Lennox-Gastaut syndrome: A prospective observational clinical study.
    Operto FF; Verrotti A; Marrelli A; Ciuffini R; Coppola G; Pastorino GMG; Striano P; Sole M; Zucca C; Manfredi V; Città S; Elia M
    Epilepsy Behav; 2020 Nov; 112():107445. PubMed ID: 32920379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Short-term efficacy and safety of rufinamide for Lennox-Gastaut syndrome].
    Takayama R; Fukumura S; Minagawa K; Watanabe T
    No To Hattatsu; 2016 Sep; 48(5):322-6. PubMed ID: 30010275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.